The FDA database recorded a supplement on 2 October 2026 to an abbreviated new drug application for clozapine held by a generic manufacturer.
The record contains the applicant and product name only. It does not say what the supplement changed, so it should not be read as a new indication, a safety communication or a label warning.
For prescribers the practical content is unchanged: the established clozapine monitoring requirements in your local protocol still apply, and the product label from the supplier is the place to look for any change. Whether this specific product is marketed in India is not stated in the record.
- Treat this as an administrative listing, not a safety notice.
- Keep current clozapine blood-monitoring routines unchanged.
- Check the manufacturer's label if you dispense this generic product.
- Availability in India is not stated in the FDA record.
Why it matters
A supplement entry alone cannot tell a prescriber whether anything about the drug has changed.
Don't overread it
A supplement listing is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free